Lumitin (conbercept) / Chengdu Kanghong Pharma - LARVOL DELTA

Efficacy and safety of intravitreal conbercept injection in treating macular oedema secondary to branch retinal vein occlusion: results from the BRAVE study. (PubMed, Br J Ophthalmol) - P3 | "Intravitreal injections of a 0.5 mg conbercept provided improvement in visual and anatomical outcomes in BRVO-ME patients with low rates of ocular and non-ocular safety events."

Journal • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Cascade-targeted intervention of the NLRP3 inflammasome and downstream angiogenesis by curcumin nanoparticles for ocular neovascularization therapy. (PubMed, Clin Transl Med) - "Cur-NPs inhibit pathological RNV through modulation of NLRP3-associated inflammatoryangiogenic signaling while improving retinal protection and intraocular retention. These findings support further evaluation of Cur-NPs as a potential upstream anti-inflammatory adjunct to VEGF-directed therapy."

Journal • Age-related Macular Degeneration • Inflammation • Ocular Inflammation • Retinal Disorders • NLRP3

Conbercept for Retinal Vein Occlusion-Associated Macular Edema: Multi-Parameter Imaging Evaluation and Construction of AI-Assisted Prognostic Model (ChiCTR) - P=N/A | N=0 | Recruiting | Sponsor: The Zhongshan Ophthalmic Center,Sun Yat-sen University; The Zhongshan Ophthalmic Center,Sun Yat-sen University

New trial • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Molecular Determinants of Intravitreal Anti-VEGF Durability: Drug Architecture, Intraocular Pharmacokinetics, Target Biology and Treatment Resistance. (PubMed, Int J Mol Sci) - "Trial evidence for ranibizumab, aflibercept, conbercept, brolucizumab and faricimab shows that extended dosing can arise from greater starting exposure, altered binding architecture or pathway expansion without a proportionate change in intrinsic ocular half-life. We propose that durability be defined as a time-to-threshold phenotype integrating active target-site exposure, biological demand, anatomical recurrence, all treatment-related procedures and safety. Standardised estimands, longitudinal human ocular sampling, spatial exposure methods and externally validated mechanism-informed models are needed to make molecular durability comparable and clinically actionable."

Journal • PK/PD data • Review • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Gene Therapies • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Correlation between the optical density ratio of subretinal fluid in OCT images and visual outcome in eyes with diabetic MacularEdema. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "In DME patients with SRD, patients with a lower baseline subretinal fluid ODR had better visual quality recovery after the anti-VEGF drug or steroid hormone treatment, identifying the optical density in subretinal fluid as a clinically relevant biomarker in diabetic macularedema."

Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Efficacy of conbercept pro re nata (PRN) versus treat-and-extend (T&E) regimens following five initial monthly doses in diabetic macular edema: a 24-month retrospective cohort study. (PubMed, Front Endocrinol (Lausanne)) - "Both the 5+PRN and 5+T&E regimens demonstrated significant improvements in visual acuity and retinal anatomical structure over the 24-month follow-up period. Over 24 months, the 5+T&E group had fewer mean injections and follow-up visits compared with the 5+PRN group, indicating that an individualized dosing strategy can reduce patient burden and healthcare costs while maintaining therapeutic efficacy."

Clinical • Journal • Retrospective data • Cardiovascular • Diabetic Macular Edema • Hematological Disorders • Ophthalmology

Eriocitrin Alleviates Choroidal Neovascularization by Promoting the Activities of Mitogen-Activated Protein Kinase Phosphatase-1 In Vivo and In Vitro. (PubMed, Curr Eye Res) - "In vivo, eriocitrin or the anti-vascular endothelial growth factor agent conbercept was administered via intravitreal injection...Eriocitrin alleviates choroidal neovascularization by promoting mitogen-activated protein kinase phosphatase-1 activity in choroidal endothelial cells, thereby inhibiting the p38 and JNK signaling pathways. These findings suggest eriocitrin as a potential therapeutic agent for choroidal neovascularization."

Journal • Preclinical • MAPK8

Annular microneedles with cationic SLNs enable minimally invasive sustained co-delivery of resveratrol and conbercept for choroidal neovascularization. (PubMed, Colloids Surf B Biointerfaces) - "Moreover, the safety of repeated microneedle administration was good. This annular microneedle-nanocomposite system enables transscleral, sustained, and targeted co-delivery to the posterior segment without the need for intravitreal puncture, offering a transformative strategy to replace frequent intravitreal injections with a synergistic, patient-compliant approach for neovascular retinal diseases."

Journal • Ophthalmology • Retinal Disorders

Differential efficacy of Conbercept vs. Ranibizumab on retinal microstructural changes in macular edema secondary to retinal vein occlusion during the loading phase. (PubMed, Front Med (Lausanne)) - "Conbercept and Ranibizumab showed comparable primary outcomes and subtle divergences in exploratory secondary OCT biomarkers during the loading phase: Conbercept yielded greater DRIL reduction, whereas Ranibizumab achieved lower CMT and IRF at early time points. These preliminary findings may generate hypotheses for an OCT phenotype-driven approach to precision anti-VEGF therapy in RVO-ME."

Journal • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Association Between Anti-vascular Endothelial Growth Factor Therapy Exposure and Visual Outcomes in Diabetic Macular Edema and Retinal Vein Occlusion. (PubMed, J Vis Exp) - "We included 332 adults who received at least one intravitreal injection of ranibizumab, aflibercept, or conbercept between January 2022 and January 2024 and had at least one post-baseline best-corrected visual acuity (BCVA) measurement. Safety events were infrequent, limiting comparison of rare events. Non-standard treatment patterns were common and associated with poorer unadjusted visual outcomes; optimizing injection exposure and treatment timing may improve real-world outcomes."

Journal • Retrospective data • Diabetic Macular Edema • Ophthalmology • Retinal Vein Occlusion

Pharmacokinetics, safety and preliminary efficacy of conbercept eye drops for corneal neovascularization: Results from phase I/IIa studies. (PubMed, Br J Clin Pharmacol) - "KH906 appears safe and well tolerated and demonstrates preliminary efficacy in reducing CorNV, with higher doses showing greater effect, supporting further clinical development."

Journal • P1/2 data • PK/PD data

Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort. (PubMed, Front Endocrinol (Lausanne)) - "Systemic metabolic status-particularly HbA1c and fasting glucose levels-and baseline ocular morphology are independently associated with of anatomical response to intravitreal Conbercept in DME. These findings highlight the clinical imperative for integrating systemic metabolic optimization into the management strategy for DME patients prior to and during anti-VEGF loading therapy."

Journal • Retrospective data • Diabetic Macular Edema • Ophthalmology

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy (clinicaltrials.gov) - P=N/A | N=146 | Recruiting | Sponsor: Wang Yusheng | Trial completion date: Dec 2026 ➔ Jan 2028

Head-to-Head • Trial completion date • Retinal Disorders • Retinopathy of Prematurity

Comparison of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization using optical coherence tomography angiography and multifocal electroretinography. (PubMed, Front Pharmacol) - "The first positive peak (P1) amplitude density in ring 1 and intraocular pressure (IOP) were recorded at baseline and the last follow-up. No serious ocular complications such as endophthalmitis and systemic adverse reactions such as myocardial infarction or cerebral infarction occurred in both groups. Compared with intravitreal ranibizumab, intravitreal conbercept had a similar therapeutic effect in improving the structure and function on ICNV but with fewer injections."

Journal • Cardiovascular • CNS Disorders • Myocardial Infarction • Ocular Infections • Ocular Inflammation • Ophthalmology

Adjuvant mecobalamin for anti-VEGF therapy in retinal vein occlusion: protocol of a single-centre, randomised, double-blinded controlled trial. (PubMed, BMJ Open) - P4 | "The experimental group will receive intravitreal injections of conbercept plus oral mecobalamin for 6 months, while the control group will receive the same conbercept regimen plus a placebo for 6 months...The results will be disseminated through conference presentations and publication in peer-reviewed international journals. NCT07133438."

Clinical • Clinical protocol • Journal • Cardiovascular • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Study of Clinical Observation and Mechanism of Conbercept Combined with Dexamethasone Intravitreal Implant in the Treatment of Refractory Macular Edema (ChiCTR) - P4 | N=60 | Recruiting | Sponsor: Shenzhen University General Hospital; Shenzhen University General Hospital

New P4 trial • Macular Edema • Ophthalmology

Efficacy and Safety of Conbercept Combined with Difrarel in the Treatment of Diabetic Macular Edema(DME) (ChiCTR) - P=N/A | N=60 | Not yet recruiting | Sponsor: Huizhou Baijirui Pharmaceutical Company Limited; Tianjin Medical University Zhu Xianyi Memorial Hospital

New trial • Diabetic Macular Edema • Ophthalmology

A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut Microbiota (clinicaltrials.gov) - P=N/A | N=80 | Not yet recruiting | Sponsor: First Affiliated Hospital of Zhejiang University

New trial • Retinal Vein Occlusion

Serum NLR, PLR and MNV characteristics as predictors of anti-VEGF plus glucocorticoid efficacy in nAMD. (PubMed, Biomark Med) - "This retrospective study included 145 patients (153 eyes) with nAMD receiving conbercept combined with dexamethasone implant...Combining serum inflammatory markers with MNV morphological characteristics enhanced predictive value for treatment response in nAMD patients receiving combination therapy. This integrated approach may facilitate personalized treatment strategies in nAMD management."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Baseline microperimetry and metabolic status predict functional outcomes in diabetic macular oedema: a prospective cohort study of anti-VEGF therapy. (PubMed, Ann Med) - "This prospective, single-centre study enrolled 58 patients with DME who received intravitreal Conbercept injection...Microperimetry is more sensitive than BCVA in assessing functional outcomes in DME. Baseline retinal functional and metabolic parameters serve as key predictors for treatment efficacy, which provides a novel theoretical basis for personalized and precise clinical management of DME."

Journal • Diabetic Macular Edema • Macular Edema • Ophthalmology

Long-Term Outcomes and Predictors of Response to Anti-VEGF Therapy for Diabetic Macular Edema in Clinical Practice. (PubMed, J Vis Exp) - "Patients are categorized into a class-level anti-VEGF treatment group (receiving ranibizumab, aflibercept, or conbercept) or a non-biologic control group (focal/grid laser or observation). By analyzing visual and anatomical trajectories alongside structural biomarkers, such as the disorganization of the retinal inner layers (DRIL), this approach provides a reproducible framework for assessing long-term outcomes in routine clinical settings. While acknowledging the limitations of a single-center retrospective design, these methods offer critical evidence to help characterize the efficacy-effectiveness gap and optimize personalized management strategies for DME."

Journal • Diabetic Macular Edema • Ophthalmology

Receptor-guided AAV capsid discovery enables robust cross-species intravitreal photoreceptor targeting and therapeutic benefit (ASGCT 2026) - "Therapeutic activity was tested using anti-VEGF (KH902) in a laser-induced CNV model and Pde6b in the rd10 model...JHW and MC are co-first authors. JHW and GG are co-corresponding authors."

Gene Therapies • Ophthalmology • Retinal Disorders

Macular Telangiectasia type 1 treated with integrated traditional Chinese acupuncture and Conbercept: a case report. (PubMed, Front Med (Lausanne)) - "The integration of traditional Chinese acupuncture with Conbercept may offer therapeutic benefits for Macular Telangiectasia type 1 in this patient. Clinically meaningful improvements were observed, including improved visual acuity, reduced metamorphopsia, and decreased central retinal thickness over follow-up."

Journal • Cardiovascular • Macular Edema • Ophthalmology • Retinal Disorders

WITHDRAWN_Alterations of the Vitreoretinal Interface in Retinal Vein Occlusion (RVO) Patients Post-Anti-VEGF Treatment (ARVO 2026) - "Among the four anti-VEGF agents administered (conbercept, ranibizumab, aflibercept, and faricimab), there were no significant differences regarding the incidence of ERM (all Ps > 0.05). PVD progression—particularly the transition from incomplete to complete PVD—significantly increases the risk of ERM formation. While PVD progression is influenced by RVO subtype and gender, the specific type of anti-VEGF agent does not significantly affect ERM incidence."

Clinical • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Association between systemic blood pressure control and outcomes of Conbercept treatment for macular edema secondary to retinal vein occlusion. (PubMed, Front Med (Lausanne)) - "Systemic BP control is associated with the short-term efficacy of Conbercept for ME secondary to RVO, and patients with well-controlled BP achieve superior visual and anatomical outcomes. This underscores the importance of co-managing systemic hypertension."

Journal • Cardiovascular • Hypertension • Macular Edema • Ophthalmology • Retinal Vein Occlusion